Abstract
Prostaglandin-H synthase exists in two isoforms, PGHS-1 and PGHS-2. PGHS-1 is present and is constitutively expressed in most cells and tissues, whereas PGHS-2 is mainly thought to mediate inflammation. Selective prostaglandin-H synthase-2 (or cyclooxygenase-2) inhibitors have been shown to be potent antiinflammatory agents with fewer side effects than currently marketed nonsteroidal antiinflammatory drugs (NSAIDs). This review addresses the main classes of the selective PGHS-2 inhibitors whose selectivity is documented by supporting PGHS-1 and PGHS-2 enzyme data. In addition, we also describe our experience in design, synthesis and pharmacological in vivo evaluation of new 1,2-benzodioxole derivatives as candidate of the selective PGHS-2 inhibitors, with special attention to molecular dynamics simulations of these derivatives attached to the active site of PGHS-2.
Keywords: nsaids, pghs-2 inhibitors, 3d-pharmacophore model, molecular dynamics, acety isalicylic acid, diclofenac, sulindac, indomethacin, piroxicam, selective pghs-2 inhibitors, 1,2-diarylcyclopentenes
Current Medicinal Chemistry
Title: Selective PGHS-2 Inhibitors: A Rational Approach for Treatment of theInflammation
Volume: 9 Issue: 8
Author(s): C. R. Rodrigues, M. P. Veloso, H. Verli, C. A.M. Fraga, A. L.P. Miranda and E. J. Barreiro
Affiliation:
Keywords: nsaids, pghs-2 inhibitors, 3d-pharmacophore model, molecular dynamics, acety isalicylic acid, diclofenac, sulindac, indomethacin, piroxicam, selective pghs-2 inhibitors, 1,2-diarylcyclopentenes
Abstract: Prostaglandin-H synthase exists in two isoforms, PGHS-1 and PGHS-2. PGHS-1 is present and is constitutively expressed in most cells and tissues, whereas PGHS-2 is mainly thought to mediate inflammation. Selective prostaglandin-H synthase-2 (or cyclooxygenase-2) inhibitors have been shown to be potent antiinflammatory agents with fewer side effects than currently marketed nonsteroidal antiinflammatory drugs (NSAIDs). This review addresses the main classes of the selective PGHS-2 inhibitors whose selectivity is documented by supporting PGHS-1 and PGHS-2 enzyme data. In addition, we also describe our experience in design, synthesis and pharmacological in vivo evaluation of new 1,2-benzodioxole derivatives as candidate of the selective PGHS-2 inhibitors, with special attention to molecular dynamics simulations of these derivatives attached to the active site of PGHS-2.
Export Options
About this article
Cite this article as:
Rodrigues R. C., Veloso P. M., Verli H., Fraga A.M. C., Miranda L.P. A. and Barreiro J. E., Selective PGHS-2 Inhibitors: A Rational Approach for Treatment of theInflammation, Current Medicinal Chemistry 2002; 9 (8) . https://dx.doi.org/10.2174/0929867024606786
DOI https://dx.doi.org/10.2174/0929867024606786 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Assessment of Glomerular and Tubular Function
Current Pediatric Reviews Gender as a Regulator of Atherosclerosis in Murine Models
Current Drug Targets The Development of Cannabinoid CBII Receptor Agonists for the Treatment of Central Neuropathies
Central Nervous System Agents in Medicinal Chemistry Chrysin’s Impact on Oxidative and Inflammation Damages in the Liver of Aged Male Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Extracellular Matrix Fragments as Regulators of Cartilage Metabolism in Health and Disease
Current Rheumatology Reviews The ModifiedGlasgow Prognostic Score and Survival in Colorectal Cancer: A Pooled Analysis of the Literature
Reviews on Recent Clinical Trials Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies
Current Pharmaceutical Design Gene-Nutrient Interaction in Type 2 Diabetes: An Appraisal of the Role of the Peroxisome Proliferator-Activated Receptor Pathway
Current Pharmacogenomics Drug-Induced Phototoxicity; An Early In Vitro Identification of Phototoxic Potential of New Drug Entities in Drug Discovery and Development
Current Drug Safety Synthesis, p38 Kinase Inhibitory and Anti-inflammatory Activity of New Substituted Benzimidazole Derivatives
Medicinal Chemistry Host Immune Responses to Aeromonas Virulence Factors
Current Immunology Reviews (Discontinued) Novel Piperazinyl Derivatives with Anti-Hyperalgesic, Anti-Allodynic and Anti-Inflammatory activities Useful for the Treatment of Neuropathic Pain
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry Application of G-CSF in Congestive Heart Failure Treatment
Current Cardiology Reviews Imino-Sugar-Based Nucleosides
Current Topics in Medicinal Chemistry Dependence of DPPH Radical Scavenging Activity of Dietary Flavonoid Quercetin on Reaction Environment
Mini-Reviews in Medicinal Chemistry Immunomodulatory Effects of Bifidobacterium longum W11 Produced Exopolysaccharide on Cytokine Production
Current Pharmaceutical Biotechnology Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance
CNS & Neurological Disorders - Drug Targets Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia
Protein & Peptide Letters